Blog
European Commission Approves Alvotech’s and Teva’s Denosumab Biosimilars
On November 24, 2025, Alvotech announced that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s PROLIA® and XGEVA® (denosumab) in the European Economic Area….
By: Goodwin